Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease
May 23, 2023
SOUTH SAN FRANCISCO, CA, May 23, 2023 – Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies...
Press Release
Vega Therapeutics Initiates Clinical Trial Program for VGA039, a First-in-Class Antibody Therapy for von Willebrand Disease
April 6, 2023
Phase 1 Clinical Trial Advances with First Subject Dosed in the E.U. and IND Accepted in the U.S...
Press Release
Vega Therapeutics launches and unveils its first-in-class antibody therapy for  von Willebrand disease at ASH Annual Meeting
December 6, 2022
With $40 million in financing to date, company has advanced lead drug candidate, VGA039, to clinical stage to treat von Willebrand disease...
Press Release
Electra Logo
November 3, 2022
Company’s lead product candidate, ELA026, is in a clinical study for a life-threatening inflammatory disease, secondary hemophagocytic lymphohistiocytosis (sHLH)
Press Release
Electra Logo
February 16, 2022
Company’s first-in-class approach to targeting of signal regulatory proteins (SIRP) enables specific depletion of pathological immune cells. Financing enables lead product candidate,...
Press Release
Star Therapeutics Logo
February 16, 2022
Drug discovery approach uncovers novel biology for treatments that can target multiple diseases with a single therapy. Star Therapeutics has formed a...
Press Release
Setting Our Sights on the Long Tail of Disease
February 15, 2022
All of us know someone who has been affected by a prevalent condition like cancer or heart disease or Alzheimer’s disease. Most...
Our Perspective

News Coverage

Adam Rosenthal is the CEO and founder of Star Therapeutics, a biotechnology company with a mission to develop life-changing therapies for as many rare diseases as possible. The company’s engine for innovation starts with identifying multiple rare diseases that share a common biology and then discovering novel therapeutics that can treat these diseases with a single therapy. Star consists…
Despite some big advances in recent years, rare disease remains a mostly uncharted wilderness with many patients left underserved. A startup with galactic ambitions now hopes to bust open a wide range of such diseases, and its first effort has eyes on a familiar cancer target. Star Therapeutics emerged from stealth Wednesday focused on cracking the code in a constellation...
The biotech has an unusual hub-and-spoke model that it believes is more efficient. Its first company was unveiled Wednesday and another is waiting in the wings. Few things are as human as gazing into the night sky. And yet, after thousands of years, we know only a little about what we’re looking at and how it all works. Space, in...
Star Therapeutics aims to develop drugs for rare diseases, many of which currently have no FDA-approved treatments. The company forms startups focused on particular areas of biology, and its first one, Electra Therapeutics, is going after a rare autoimmune condition that can become fatal in less than four years. Rare disease offers plenty of drug research opportunities simply because there...